Also found in: Medical.
BRAFBlack Rock Arts Foundation
BRAFBaton Rouge Area Foundation
BRAFBedfordshire Rural Affairs Forum (England, UK)
BRAFBraking Action Fair (aviation)
BRAFBoothbay Region Art Foundation (Boothbay Harbor, ME)
BRAFBookstore Requisition Attachment Form (USF)
References in periodicals archive ?
Today s EU approval is based primarily on results of the Phase III coBRIM study, which showed that people with previously untreated BRAF V600 mutation-positive advanced melanoma who were being treated with the MEK inhibitor Cotellic in combination with Zelboraf lived a median of one year (12.
Data further establish Tafinlar + Mekinist as a standard of care to treat BRAF mutation-positive disease, the most common metastatic melanoma mutation1
The BRAF Commander distributed certificates to the graduates and prizes to high-achievers.
Sosman, professor of medicine at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, said that after performing a sophisticated analysis called targeted next-generation sequencing, it appears that about 8 percent of pan-negative melanomas have BRAF fusions.
Ventana), a member of the Roche Group, today announced the global launch of the industry's first BRAF V600E immunohistochemistry (IHC) test[sup.
But the results do indicate that BRAF status may someday serve as a marker of sensitivity to aspirin therapy, said Reiko Nishihara, Ph.
There has been a clear unmet medical need for a robust, well-validated, and reproducible BRAF mutation test that can be performed on DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tissue samples.
The cobas BRAF Mutation Test is a companion diagnostic developed by Roche to identify patients with melanoma tumors that carry a mutated form of the BRAF gene, and will be eligible for treatment with Zelboraf (vemurafenib), once it is commercially available.
In the new study, Chapman, Keith Flaherty of Harvard Medical School in Boston and colleagues treated 48 patients who had BRAF-related metastatic melanoma with PLX4032, a drug devised to stop the mutant BRAF protein from triggering cell growth.
The drug, PLX4032, inhibits faulty BRAF and prevents it stimulating the cancer.
KRAS or BRAF mutations are present in nearly half of CRC tumors.
They found that damage to the BRAF gene can lead to melanoma - the most deadly form of skin cancer.